Epitranscriptomic approach: To improve the efficacy of icb therapy by co‐targeting intracellular checkpoint cish
Cells, ISSN: 2073-4409, Vol: 10, Issue: 9
2021
- 6Citations
- 39Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations6
- Citation Indexes6
- CrossRef6
- Captures39
- Readers39
- 39
Article Description
Cellular immunotherapy has recently emerged as a fourth pillar in cancer treatment co-joining surgery, chemotherapy and radiotherapy. Where, the discovery of immune checkpoint blockage or inhibition (ICB/ICI), anti‐PD‐1/PD‐L1 and anti‐CTLA4‐based, therapy has revolution-ized the class of cancer treatment at a different level. However, some cancer patients escape this immune surveillance mechanism and become resistant to ICB‐therapy. Therefore, a more advanced or an alternative treatment is required urgently. Despite the functional importance of epitran-scriptomics in diverse clinico‐biological practices, its role in improving the efficacy of ICB therapeutics has been limited. Consequently, our study encapsulates the evidence, as a possible strategy, to improve the efficacy of ICB‐therapy by co‐targeting molecular checkpoints especially NA‐modifi-cation machineries which can be reformed into RNA modifying drugs (RMD). Here, we have ex-plained the mechanism of individual RNA‐modifiers (editor/writer, eraser/remover, and effec-tor/reader) in overcoming the issues associated with high‐dose antibody toxicities and drug‐re-sistance. Moreover, we have shed light on the importance of suppressor of cytokine signaling (SOCS/CISH) and microRNAs in improving the efficacy of ICB‐therapy, with brief insight on the current monoclonal antibodies undergoing clinical trials or already approved against several solid tumor and metastatic cancers. We anticipate our investigation will encourage researchers and clini-cians to further strengthen the efficacy of ICB‐therapeutics by considering the importance of epi-transcriptomics as a personalized medicine.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know